glp 1 antagonist drugs Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment The GLP-1 Agonists and Obesity:

Ida S, Kaneko R, Imataka K, Okubo K, Shirakura Y, Azuma K, et al

Preclinical data indicated that tirzepatide exhibited an affinity for GIPR equivalent to GIP binding, while its affinity for GLP-1R was approximately five times weaker compared to GLP-1 (63)

[DOI] [PMC free article] [PubMed] [Google Scholar] 742.Jelsing J., Vrang N., Hansen G., Raun K., Tang-Christensen M., Knudsen L.B

Orforglipron 36 mg was superior to semaglutide 14mg with respect to mean change in glycated haemoglobin (HbA1c) in patients with Type 2 diabetes inadequately controlled with metformin over 52 weeks

Immediately after being secreted, GLP-1 enters the capillaries and is rapidly degraded by dipeptidyl peptidase-4 (DPP-4)

171 IR is still the key link between diabetes and PD and may impair nigrostriatal dopamine function, 172 exacerbate nigrostriatal DA depletion, 173 and enhance cognitive impairment 174 and behavioral abnormalities